Entrada Therapeutics, Inc. Common Stock (TRDA) is a publicly traded Healthcare sector company. As of May 21, 2026, TRDA trades at $6.18 with a market cap of $228.65M and a P/E ratio of -1.49. TRDA moved +6.73% today. Year to date, TRDA is -42.48%; over the trailing twelve months it is -26.70%. Its 52-week range spans $4.93 to $21.79. Analyst consensus is strong buy with an average price target of $19.50. Rallies surfaces TRDA's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Entradas shares plunge after DMD therapy misses primary efficacy endpoints: Shares of Entradas plunged after its DMD candidate failed to meet key efficacy endpoints, with trial results showing no significant improvement on primary functional measures. Investors sold off shares following the efficacy shortfall in the Duchenne muscular dystrophy program.
| Metric | Value |
|---|---|
| Price | $6.18 |
| Market Cap | $228.65M |
| P/E Ratio | -1.49 |
| EPS | $-3.99 |
| Dividend Yield | 0.00% |
| 52-Week High | $21.79 |
| 52-Week Low | $4.93 |
| Volume | 1 |
| Avg Volume | 0 |
| Revenue (TTM) | $5.74M |
| Net Income | $-166.12M |
| Gross Margin | 0.00% |
8 analysts cover TRDA: 0 strong buy, 7 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $19.50.